Lista de obras - Silvia Marsoni - Dominio Público Uruguay

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma

artículo científico

A lesson from vorinostat in pleural mesothelioma

artículo científico publicado en 2015

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

artículo científico publicado en 2011

A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies

scientific article published on 27 December 2010

A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer

artículo científico publicado en 2013

A proposal for a new approach to intergroup cancer trials

Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?

artículo científico publicado en 2013

Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial

artículo científico publicado en 1998

An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens

artículo científico publicado en 2012

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

artículo científico

Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network.

artículo científico publicado en 2003

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex

artículo científico publicado en 2000

Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.

artículo científico publicado en 2009

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

artículo científico publicado en 2015

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors

artículo científico publicado en 2006

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

artículo científico publicado en 2011

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

artículo científico publicado en 2010

Dilemmas in the development of cytoxic drug analogues

artículo científico publicado el 1 de enero de 1992

Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

article

Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort

artículo científico publicado en 2016

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

artículo científico publicado en 2016

Early ovarian cancer and the icon trials

artículo científico publicado en 1992

Early-onset colorectal cancer in young individuals

artículo científico publicado en 2018

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

artículo científico publicado en 2013

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

scientific article published on 01 July 2015

Fluorouracil and folinic acid in colon cancer

artículo científico publicado en 1995

Fluorouracil and folinic acid in colon cancer. IMPACT Investigators

Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer

artículo científico publicado en 2010

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver

Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.

artículo científico publicado en 2011

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

artículo científico publicado en 2012

Integrating liquid biopsies into the management of cancer

artículo científico publicado en 2017

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy

artículo científico publicado en 2015

Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial

artículo científico publicado en 2003

New Omics Information for Clinical Trial Utility in the Primary Setting

artículo científico publicado en 2011

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database

artículo científico publicado en 2014

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors

artículo científico publicado en 2012

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

artículo científico publicado en 2020

Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.

artículo científico publicado en 2010

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

artículo científico publicado en 2009

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing

artículo científico publicado en 2006

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule

artículo científico publicado en 2007

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

artículo científico publicado en 2004

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

artículo científico publicado en 2010

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin ⬇️

artículo científico publicado el 21 de agosto de 2012

Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (hac) vs. cisplatin, adriamycin, cyclophosphamide (pac) in advanced ovarian cancer: long-term results

scientific article published on 01 March 1991

Role of Cetuximab in the Treatment of Patients With NSCLC: Are We Throwing Out the Baby With the Bath Water?

scientific article published on 28 June 2010

Spiromustine: a new agent entering clinical trials

artículo científico publicado en 1983

Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.

artículo científico publicado en 2011

The genomic landscape of response to EGFR blockade in colorectal cancer.

artículo científico publicado en 2015

Tiazofurin: a new antitumor agent.

artículo científico publicado en 1984

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

artículo científico publicado en 2005

Treating childhood acute lymphoblastic leukaemia (ALL): Summary of ten years' experience in Italy

article

VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma

artículo científico publicado en 1982

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

artículo científico publicado en 2015

Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies.

artículo científico publicado en 2012

Vincristine and bleomycin do not interfere with infusional plasma levels of methotrexate

artículo científico publicado en 1981

Lista de obras de Silvia Marsoni

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma

A lesson from vorinostat in pleural mesothelioma

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies

A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer

A proposal for a new approach to intergroup cancer trials

Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?

Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial

An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network.

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex

Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

Dilemmas in the development of cytoxic drug analogues

Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Early ovarian cancer and the icon trials

Early-onset colorectal cancer in young individuals

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Fluorouracil and folinic acid in colon cancer

Fluorouracil and folinic acid in colon cancer. IMPACT Investigators

Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver

Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

Integrating liquid biopsies into the management of cancer

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy

Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial

New Omics Information for Clinical Trial Utility in the Primary Setting

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin ⬇️

Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (hac) vs. cisplatin, adriamycin, cyclophosphamide (pac) in advanced ovarian cancer: long-term results

Role of Cetuximab in the Treatment of Patients With NSCLC: Are We Throwing Out the Baby With the Bath Water?

Spiromustine: a new agent entering clinical trials

Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.

The genomic landscape of response to EGFR blockade in colorectal cancer.

Tiazofurin: a new antitumor agent.

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

Treating childhood acute lymphoblastic leukaemia (ALL): Summary of ten years' experience in Italy

VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies.

Vincristine and bleomycin do not interfere with infusional plasma levels of methotrexate